French Study Prompts FDA Concern About Growth Hormone

The Food and Drug Administration (FDA) has undertaken a review of recombinant human growth hormone (somatropin) after a French study determined that some kids who take it because they are abnormally short may be at a small increased risk of death.

The FDA does not recommend that patients stop taking recombinant human growth hormone before talking to their physicians, as it believes the benefit of the hormone still outweighs its potential risks. However, the FDA is now reviewing all available information on this potential risk and plans to issue new recommendations, if necessary, once the review is completed.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Published In: Administrative Agency Updates, Consumer Protection Updates, Health Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Patrick Malone & Associates P.C. | DC Injury Lawyers | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

CONNECT

About Patrick Malone: Patrick Malone is a leading patient safety advocate and attorney who... View Profile »


Follow Patrick Malone & Associates P.C. | DC Injury Lawyers:

Reporters on Deadline